MK-0518

Medical Advocates
Raltegravir (Isentress/MK-0518)

Conference Citations

XX International AIDS Conference
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention
XIX International AIDS Conference

Raltegravir Main Page Main New/Newsworthy Home Page

Last Update: July 30, 2015
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

XX International AIDS Conference

Primary mutations that confer resistance to raltegravir and elvitegravir are incompatible with the R263K mutation that is associated with low-level resistance to dolutegravir.
K. Anstett, T. Mesplede, P. Quashie, et al
Abstract

Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants
K. Tsuchiya, T. Hayashida, A. Hamada, et al
Abstract
Comparison of effects of atazanavir, raltegravir, or darunavir with FTC/tenofovir on biomarkers of systemic inflammation, macrophage and T cell activation: ACTG A5260s
T. Kelesidis, T.T.T. Tran, G.A. McComsey, et al
Abstract

Raltegravir (RAL) therapy is associated with reduced microbial translocation (MT) and monocyte activation in HIV infected subjects naïve to antiretroviral therapy (ART)
D.M. Asmuth, Z.-M. Ma, T. Hayes, et al
Abstract

Outcomes of Botswana´s highly treatment experienced adults on raltegravir and darunavir containing ART regimens at Princess Marina Hospital in Gaborone
A. Avalos, M. Haverkamp, V. Letsatsi, et al
Abstract

7th IAS Conference on HIV Pathogenesis, Treatment and
Prevention

POSTER
RADAR study: week 48 safety and efficacy of raltegravir combined with boosted darunavir compared to tenofovir/emtricitabine combined
with boosted darunavir in antiretroviral-naive patients. Impact on bone
R. Bedimo1, H. Drechsler, J. Cutrell, et al
Poster Abstract

Raltegravir/etravirine dual therapy as a virologically safe treatment option in suppressed HIV-1-infected patients without previous NNRTI failure
R. Calin, M.-A. Valantin, A. Simon, et al
Abstract
Safety, tolerability and adherence with raltegravir-emtricitabine-tenofovir as HIV non-occupational post-exposure prophylaxis in men who have sex with men
J. McAlliste, A. McNulty, P. Read, et al
Abstract
The feasibility of switching efavirenz (EFV)-based highly active antiretroviral therapy to raltegravir (RAL)-based therapy in HIV-infected individuals with central nervous system (CNS) toxicity: a phase IV open label pilot study
H.M. Yapa, L. Waters, J. Rowlands, et al
Abstract
Modelling HIV PrEP in humanized mice: pharmacokinetic studies on antiretroviral drugs raltegravir, tenofovir and maraviroc
R. Akkina, M. Veselinovic C.P. Neff, , et al
Abstract

XIX International AIDS Conference

A WEEK-IN-REVIEW FEATURED REPORT
Long-term safety and efficacy of raltegravir (RAL)-based versus efavirenz (EFV)-based combination therapy
in treatment-naïve HIV-1-infected patients: final 5-year double-blind results from STARTMRK
J. Rockstroh, E. DeJesus M. , M. Saag, et al
Abstract
Effects of raltegravir (RAL) combined with tenofovir (TDF) and emtricitabine (FTC) on body shape, bone density and
lipids in HIV+ African Americans initiating therapy: metabolic outcomes of the UNC-REAL study
D. Wohl, L. Young, W. Hyslop, et al
Abstract
Horizontal transmission of HIV-1 exhibiting resistance to four antiretroviral drug classes, including integrase inhibitors
C. Walworth, D. Ward, L. Napolitano, et al
Abstract
Treatment optimization in HIV-2-positive patients
P. Andrade, J. Soares, C. Caldas, et al
Abstract
IMPAACT P1066: raltegravir (RAL) safety and efficacy in HIV infected (+) youth two to 18 years of age through week 48
S. Nachman, E. Acosta, N. Zheng, et al
Abstract
Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir tablets in HIV-positive patients given the
drug by swallowing or by chewing
C. Gervasoni, S. Baldelli, M. Cerea, et al
Abstract
Outcomes of third-line antiretroviral therapy containing darunavir, etravirine or raltegravir in Thai children with HIV infection
J. Ananworanich,, W. Prasitsuebsai, P. Kosalaraksa, et al
Abstract
Treatment optimization in HIV-2-positive patients
P. Andrade, J. Soares, C. Caldas, et al
Abstract
Low rates of integrase resistance for elvitegravir and raltegravir through week 96 in the phase 3 clinical study GS-US-183-0145
N.A. Margot, M. Rhee, J. Szwarcberg, M.D. Miller, et al
Abstract

Raltegravir Main Page

Main New/Newsworthy

Home Page

Raltegravir Conference Citations

Safety, tolerability and adherence with raltegravir-emtricitabine-tenofovir as HIV non-occupational post-exposure prophylaxis in men who have sex with men
J. McAlliste, A. McNulty, P. Read, et al
Abstract

The feasibility of switching efavirenz (EFV)-based highly active antiretroviral therapy to raltegravir (RAL)-based therapy in HIV-infected individuals with central nervous system (CNS) toxicity: a phase IV open label pilot study
H.M. Yapa, L. Waters, J. Rowlands, et al
Abstract

Safety, tolerability and adherence with raltegravir-emtricitabine-tenofovir as HIV non-occupational post-exposure prophylaxis in men who have sex with men J. McAlliste, A. McNulty, P. Read, et al Abstract

The feasibility of switching efavirenz (EFV)-based highly active antiretroviral therapy to raltegravir (RAL)-based therapy in HIV-infected individuals with central nervous system (CNS) toxicity: a phase IV open label pilot study H.M. Yapa, L. Waters, J. Rowlands, et al Abstract

Safety, tolerability and adherence with raltegravir-emtricitabine-tenofovir as HIV non-occupational post-exposure prophylaxis in men who have sex with men
J. McAlliste, A. McNulty, P. Read, et al
Abstract

The feasibility of switching efavirenz (EFV)-based highly active antiretroviral therapy to raltegravir (RAL)-based therapy in HIV-infected individuals with central nervous system (CNS) toxicity: a phase IV open label pilot study
H.M. Yapa, L. Waters, J. Rowlands, et al
Abstract